Cours en clôture
Autres places de cotation
|
||
- USD | - |
|
2022 | La Jolla Pharmaceutical annonce des changements de direction | CI |
2022 | Innoviva, Inc. (NasdaqGS:INVA) a finalisé l'acquisition de La Jolla Pharmaceutical Company (NasdaqCM:LJPC). | CI |
Dirigeants | Titre | Age | Depuis |
---|---|---|---|
Michael Hearne
DFI | Director of Finance/CFO | 61 | 01/06/20 |
Tony Hodges
CTO | Chief Tech/Sci/R&D Officer | - | 12/09/21 |
Luke Seikkula
COO | Chief Operating Officer | 60 | 01/01/19 |
Administrateurs | Titre | Age | Depuis |
---|---|---|---|
Marianne Zhen
BRD | Director/Board Member | 55 | 22/08/22 |
Pavel Raifeld
BRD | Director/Board Member | 40 | 22/08/22 |
Varia. 1 janv. | Capi. | |
---|---|---|
+20,63% | 127 Md | |
+23,21% | 117 Md | |
+26,43% | 27,67 Md | |
-20,17% | 20,33 Md | |
-16,36% | 16,79 Md | |
-18,07% | 15,63 Md | |
+11,92% | 14,84 Md | |
-47,70% | 14,65 Md | |
+58,32% | 14,43 Md |
- Bourse
- Actions
- Action LJPC
- Action